Figures & data
Table 1 Patient characteristics
Table 2 Clinical and pathological responses
Figure 1 Comparison of the efficacy of nab-paclitaxel and paclitaxel in subgroup analysis.
Abbreviations: BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; HER2, human epidermal receptor-2; cT, clinical tumor stage; cN, clinical lymph nodal stage.
![Figure 1 Comparison of the efficacy of nab-paclitaxel and paclitaxel in subgroup analysis.Abbreviations: BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; HER2, human epidermal receptor-2; cT, clinical tumor stage; cN, clinical lymph nodal stage.](/cms/asset/2cb640f5-fbad-4aa8-bbd1-93dcb85cddcf/dijn_a_77000_f0001_b.jpg)
Table 3 Common treatment-related grade 1–4 adverse events